| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Elastin | 37 | 2021 | 116 | 8.680 |
Why?
|
| Hydrolyzable Tannins | 12 | 2021 | 25 | 6.300 |
Why?
|
| Bioprosthesis | 24 | 2017 | 101 | 5.770 |
Why?
|
| Heart Valve Prosthesis | 26 | 2017 | 222 | 5.200 |
Why?
|
| Aortic Aneurysm, Abdominal | 8 | 2021 | 139 | 4.000 |
Why?
|
| Calcinosis | 25 | 2017 | 241 | 3.570 |
Why?
|
| Nanoparticles | 8 | 2021 | 254 | 3.300 |
Why?
|
| Vascular Calcification | 8 | 2021 | 131 | 2.940 |
Why?
|
| Myocytes, Smooth Muscle | 11 | 2021 | 144 | 2.480 |
Why?
|
| Neomycin | 7 | 2017 | 56 | 2.360 |
Why?
|
| Aorta, Abdominal | 7 | 2021 | 97 | 2.300 |
Why?
|
| Glycosaminoglycans | 12 | 2015 | 88 | 2.240 |
Why?
|
| Biocompatible Materials | 15 | 2015 | 247 | 2.070 |
Why?
|
| Cross-Linking Reagents | 12 | 2017 | 80 | 1.940 |
Why?
|
| Elastic Tissue | 7 | 2022 | 28 | 1.910 |
Why?
|
| Drug Delivery Systems | 4 | 2021 | 236 | 1.850 |
Why?
|
| Edetic Acid | 4 | 2019 | 29 | 1.820 |
Why?
|
| Polyphenols | 4 | 2021 | 34 | 1.810 |
Why?
|
| Matrix Metalloproteinases | 7 | 2019 | 223 | 1.790 |
Why?
|
| Glutaral | 15 | 2017 | 41 | 1.790 |
Why?
|
| Aorta | 11 | 2022 | 316 | 1.790 |
Why?
|
| Swine | 30 | 2021 | 672 | 1.750 |
Why?
|
| Rats | 38 | 2021 | 5300 | 1.640 |
Why?
|
| Fibroblasts | 10 | 2021 | 902 | 1.610 |
Why?
|
| Aortic Valve | 13 | 2012 | 249 | 1.600 |
Why?
|
| Animals | 65 | 2022 | 20881 | 1.580 |
Why?
|
| Osteogenesis | 8 | 2021 | 152 | 1.580 |
Why?
|
| Rats, Sprague-Dawley | 25 | 2021 | 2083 | 1.470 |
Why?
|
| Extracellular Matrix | 10 | 2021 | 493 | 1.430 |
Why?
|
| Drug Carriers | 4 | 2020 | 90 | 1.380 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 4 | 2021 | 59 | 1.370 |
Why?
|
| Tissue Engineering | 8 | 2021 | 212 | 1.330 |
Why?
|
| Matrix Metalloproteinase 9 | 8 | 2018 | 160 | 1.240 |
Why?
|
| Immunoconjugates | 2 | 2020 | 26 | 1.220 |
Why?
|
| Collagen | 14 | 2021 | 636 | 1.190 |
Why?
|
| Chelation Therapy | 2 | 2019 | 17 | 1.150 |
Why?
|
| Disease Models, Animal | 17 | 2021 | 2550 | 1.080 |
Why?
|
| Pericardium | 6 | 2017 | 97 | 1.070 |
Why?
|
| Pancreatic Elastase | 9 | 2022 | 33 | 1.050 |
Why?
|
| Serum Albumin, Bovine | 3 | 2021 | 43 | 1.030 |
Why?
|
| Durapatite | 3 | 2015 | 33 | 1.000 |
Why?
|
| Gold | 3 | 2020 | 76 | 0.980 |
Why?
|
| Osteoclasts | 2 | 2021 | 132 | 0.970 |
Why?
|
| Metal Nanoparticles | 3 | 2020 | 88 | 0.950 |
Why?
|
| Tissue Fixation | 4 | 2017 | 58 | 0.940 |
Why?
|
| Chelating Agents | 2 | 2014 | 47 | 0.930 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2019 | 317 | 0.910 |
Why?
|
| Cells, Cultured | 15 | 2021 | 2673 | 0.890 |
Why?
|
| Pulmonary Emphysema | 2 | 2021 | 71 | 0.860 |
Why?
|
| Aortic Diseases | 3 | 2013 | 113 | 0.850 |
Why?
|
| Matrix Metalloproteinase 2 | 9 | 2015 | 145 | 0.850 |
Why?
|
| Aortic Aneurysm | 3 | 2020 | 77 | 0.810 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2021 | 31 | 0.780 |
Why?
|
| Skin Aging | 1 | 2021 | 8 | 0.770 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 35 | 0.760 |
Why?
|
| Skin Care | 1 | 2021 | 14 | 0.760 |
Why?
|
| Carbodiimides | 3 | 2017 | 6 | 0.750 |
Why?
|
| Fixatives | 4 | 2017 | 24 | 0.750 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2017 | 164 | 0.740 |
Why?
|
| Tunica Media | 2 | 2014 | 33 | 0.710 |
Why?
|
| Angiotensin II | 1 | 2021 | 220 | 0.710 |
Why?
|
| Calcium | 10 | 2013 | 929 | 0.680 |
Why?
|
| Arteries | 2 | 2019 | 108 | 0.680 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 234 | 0.680 |
Why?
|
| Male | 31 | 2021 | 37321 | 0.640 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2009 | 48 | 0.620 |
Why?
|
| Calcium Chloride | 4 | 2016 | 38 | 0.590 |
Why?
|
| Mice | 10 | 2022 | 8474 | 0.570 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 127 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.560 |
Why?
|
| Calcium Chelating Agents | 1 | 2016 | 5 | 0.560 |
Why?
|
| Emphysema | 1 | 2016 | 32 | 0.540 |
Why?
|
| Doxycycline | 1 | 2016 | 49 | 0.540 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 240 | 0.530 |
Why?
|
| Antioxidants | 1 | 2018 | 304 | 0.520 |
Why?
|
| Phenylalanine | 1 | 2015 | 22 | 0.520 |
Why?
|
| Tannins | 2 | 2006 | 17 | 0.520 |
Why?
|
| Polyesters | 1 | 2015 | 55 | 0.510 |
Why?
|
| Smad5 Protein | 1 | 2015 | 3 | 0.510 |
Why?
|
| Thiophenes | 1 | 2015 | 76 | 0.510 |
Why?
|
| Transforming Growth Factor beta1 | 4 | 2013 | 126 | 0.500 |
Why?
|
| Ethanol | 6 | 2010 | 893 | 0.500 |
Why?
|
| Injections, Intravenous | 3 | 2021 | 215 | 0.490 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2015 | 57 | 0.490 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 3 | 2014 | 16 | 0.480 |
Why?
|
| Glucose | 3 | 2022 | 307 | 0.480 |
Why?
|
| Antibodies | 3 | 2021 | 241 | 0.470 |
Why?
|
| Tropoelastin | 1 | 2014 | 2 | 0.470 |
Why?
|
| Tissue Preservation | 2 | 2005 | 44 | 0.470 |
Why?
|
| Cattle | 9 | 2017 | 475 | 0.460 |
Why?
|
| Tunica Intima | 1 | 2014 | 59 | 0.460 |
Why?
|
| Lactic Acid | 1 | 2014 | 86 | 0.440 |
Why?
|
| Aluminum Compounds | 3 | 2004 | 10 | 0.430 |
Why?
|
| Chlorides | 3 | 2004 | 68 | 0.430 |
Why?
|
| Hyaluronoglucosaminidase | 3 | 2008 | 43 | 0.430 |
Why?
|
| Tenascin | 2 | 2004 | 39 | 0.420 |
Why?
|
| Cell Differentiation | 5 | 2021 | 1034 | 0.420 |
Why?
|
| Biomechanical Phenomena | 7 | 2017 | 368 | 0.420 |
Why?
|
| Heart Valves | 2 | 2011 | 171 | 0.410 |
Why?
|
| Materials Testing | 6 | 2015 | 263 | 0.410 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 201 | 0.410 |
Why?
|
| Cell Culture Techniques | 5 | 2015 | 189 | 0.410 |
Why?
|
| Macrophages | 4 | 2021 | 647 | 0.400 |
Why?
|
| Polymers | 1 | 2014 | 244 | 0.400 |
Why?
|
| Venae Cavae | 1 | 2011 | 16 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 1026 | 0.400 |
Why?
|
| Tensile Strength | 6 | 2017 | 90 | 0.400 |
Why?
|
| Calorimetry, Differential Scanning | 4 | 2014 | 27 | 0.390 |
Why?
|
| Prostheses and Implants | 4 | 2007 | 159 | 0.370 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1293 | 0.360 |
Why?
|
| X-Ray Microtomography | 2 | 2020 | 50 | 0.350 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 56 | 0.340 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 51 | 0.330 |
Why?
|
| Time Factors | 6 | 2017 | 4655 | 0.300 |
Why?
|
| Equipment Failure Analysis | 3 | 2015 | 121 | 0.300 |
Why?
|
| Protein-Lysine 6-Oxidase | 3 | 2018 | 14 | 0.300 |
Why?
|
| Skin | 4 | 2021 | 451 | 0.290 |
Why?
|
| Immunohistochemistry | 6 | 2009 | 1174 | 0.290 |
Why?
|
| Alkaline Phosphatase | 4 | 2014 | 71 | 0.290 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 117 | 0.290 |
Why?
|
| Transforming Growth Factor beta | 2 | 2006 | 384 | 0.270 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 217 | 0.260 |
Why?
|
| Prosthesis Failure | 3 | 2003 | 130 | 0.260 |
Why?
|
| Guided Tissue Regeneration | 1 | 2005 | 6 | 0.260 |
Why?
|
| Phenols | 1 | 2006 | 73 | 0.260 |
Why?
|
| In Vitro Techniques | 3 | 2014 | 765 | 0.260 |
Why?
|
| Proteolysis | 2 | 2016 | 97 | 0.260 |
Why?
|
| Blood Vessels | 1 | 2006 | 102 | 0.260 |
Why?
|
| Flavonoids | 1 | 2006 | 109 | 0.260 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2005 | 43 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 2791 | 0.240 |
Why?
|
| Osteocalcin | 2 | 2015 | 37 | 0.240 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1664 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1745 | 0.230 |
Why?
|
| Osteoblasts | 2 | 2015 | 99 | 0.230 |
Why?
|
| Collagenases | 3 | 2011 | 34 | 0.230 |
Why?
|
| Inflammation | 2 | 2021 | 1030 | 0.220 |
Why?
|
| Temperature | 3 | 2011 | 341 | 0.210 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2014 | 127 | 0.210 |
Why?
|
| Lung | 2 | 2018 | 849 | 0.200 |
Why?
|
| Signal Transduction | 3 | 2018 | 2689 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2001 | 18 | 0.200 |
Why?
|
| Stress, Mechanical | 2 | 2015 | 208 | 0.200 |
Why?
|
| Tidal Volume | 1 | 2021 | 17 | 0.200 |
Why?
|
| Transplantation, Heterologous | 2 | 2017 | 122 | 0.200 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2021 | 17 | 0.190 |
Why?
|
| Bone Resorption | 1 | 2021 | 64 | 0.190 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2022 | 134 | 0.190 |
Why?
|
| Protein Denaturation | 2 | 2014 | 27 | 0.190 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 187 | 0.190 |
Why?
|
| RANK Ligand | 1 | 2021 | 73 | 0.190 |
Why?
|
| Humans | 13 | 2021 | 68618 | 0.180 |
Why?
|
| Ultraviolet Rays | 1 | 2021 | 130 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 137 | 0.180 |
Why?
|
| Monocytes | 1 | 2021 | 210 | 0.180 |
Why?
|
| Aneurysm | 1 | 2020 | 53 | 0.170 |
Why?
|
| Microscopy | 1 | 2020 | 64 | 0.170 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 567 | 0.170 |
Why?
|
| Drug Combinations | 3 | 2007 | 304 | 0.170 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1692 | 0.170 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 6 | 2007 | 72 | 0.170 |
Why?
|
| Receptors, LDL | 1 | 2019 | 72 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 370 | 0.160 |
Why?
|
| Tissue Distribution | 1 | 2019 | 282 | 0.160 |
Why?
|
| Disease Progression | 2 | 2015 | 1038 | 0.160 |
Why?
|
| Complex Mixtures | 1 | 2018 | 14 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 145 | 0.150 |
Why?
|
| Kinetics | 2 | 2014 | 1047 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2021 | 597 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 333 | 0.150 |
Why?
|
| Hexosamines | 2 | 2008 | 10 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2020 | 453 | 0.150 |
Why?
|
| Fibrillins | 2 | 2015 | 24 | 0.150 |
Why?
|
| Water | 1 | 1998 | 230 | 0.140 |
Why?
|
| Cell Proliferation | 5 | 2015 | 1174 | 0.140 |
Why?
|
| Heterografts | 1 | 2017 | 70 | 0.140 |
Why?
|
| Body Weight | 1 | 2019 | 554 | 0.140 |
Why?
|
| Microfilament Proteins | 2 | 2015 | 102 | 0.140 |
Why?
|
| Arachnida | 1 | 2016 | 2 | 0.140 |
Why?
|
| Drug Liberation | 1 | 2016 | 17 | 0.140 |
Why?
|
| Contrast Media | 1 | 2020 | 595 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2016 | 39 | 0.140 |
Why?
|
| Solubility | 1 | 2016 | 134 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2016 | 34 | 0.140 |
Why?
|
| Histocytochemistry | 1 | 2016 | 149 | 0.140 |
Why?
|
| Cell Adhesion | 3 | 2009 | 324 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2008 | 236 | 0.130 |
Why?
|
| Particle Size | 1 | 2016 | 201 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 649 | 0.130 |
Why?
|
| Phenotype | 1 | 2019 | 947 | 0.130 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 35 | 0.130 |
Why?
|
| RAW 264.7 Cells | 1 | 2015 | 42 | 0.130 |
Why?
|
| Elastic Modulus | 1 | 2015 | 25 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 499 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2003 | 1615 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 626 | 0.130 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2015 | 10 | 0.130 |
Why?
|
| Powders | 1 | 2015 | 32 | 0.130 |
Why?
|
| Naphthalenes | 1 | 2015 | 47 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2015 | 147 | 0.120 |
Why?
|
| Electrophoresis | 2 | 2007 | 69 | 0.120 |
Why?
|
| Albumins | 1 | 2014 | 72 | 0.120 |
Why?
|
| Graft Survival | 1 | 2017 | 465 | 0.120 |
Why?
|
| Aggrecans | 1 | 2014 | 13 | 0.120 |
Why?
|
| Collagen Type II | 1 | 2014 | 13 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2007 | 682 | 0.120 |
Why?
|
| Chondrogenesis | 1 | 2014 | 15 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 945 | 0.120 |
Why?
|
| Prosthesis Design | 1 | 2015 | 301 | 0.120 |
Why?
|
| Catechin | 1 | 2014 | 26 | 0.120 |
Why?
|
| Models, Cardiovascular | 3 | 2003 | 133 | 0.120 |
Why?
|
| Pentetic Acid | 1 | 2013 | 18 | 0.120 |
Why?
|
| Myosin Heavy Chains | 1 | 2014 | 49 | 0.120 |
Why?
|
| Tissue Scaffolds | 2 | 2021 | 111 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 492 | 0.110 |
Why?
|
| Tretinoin | 2 | 2021 | 92 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2015 | 190 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2015 | 178 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2007 | 346 | 0.110 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 56 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2016 | 7029 | 0.110 |
Why?
|
| Regeneration | 1 | 2014 | 105 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 261 | 0.110 |
Why?
|
| Nitric Oxide | 1 | 2015 | 382 | 0.110 |
Why?
|
| Sheep | 4 | 2003 | 128 | 0.110 |
Why?
|
| Actins | 1 | 2014 | 249 | 0.100 |
Why?
|
| Heart Valve Diseases | 2 | 2003 | 123 | 0.100 |
Why?
|
| Sus scrofa | 1 | 2011 | 74 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2014 | 204 | 0.100 |
Why?
|
| Protein Stability | 1 | 2011 | 90 | 0.100 |
Why?
|
| DNA | 2 | 2004 | 597 | 0.100 |
Why?
|
| Printing | 2 | 2008 | 9 | 0.090 |
Why?
|
| Amino Acids | 2 | 2003 | 131 | 0.090 |
Why?
|
| Stents | 1 | 2015 | 657 | 0.090 |
Why?
|
| Polyethylene Glycols | 2 | 2009 | 149 | 0.090 |
Why?
|
| Implants, Experimental | 2 | 2000 | 15 | 0.090 |
Why?
|
| Hydroxyproline | 1 | 2009 | 33 | 0.080 |
Why?
|
| Hydrogels | 1 | 2009 | 54 | 0.080 |
Why?
|
| Collagen Type I | 2 | 2007 | 175 | 0.080 |
Why?
|
| Cell Survival | 3 | 2009 | 901 | 0.080 |
Why?
|
| Elasticity | 2 | 2007 | 103 | 0.080 |
Why?
|
| Elastomers | 1 | 2008 | 1 | 0.080 |
Why?
|
| Molecular Structure | 2 | 2008 | 397 | 0.080 |
Why?
|
| Polyurethanes | 1 | 2008 | 21 | 0.080 |
Why?
|
| Mitral Valve | 2 | 2001 | 166 | 0.080 |
Why?
|
| Aged | 2 | 2014 | 14862 | 0.080 |
Why?
|
| Hydrolysis | 2 | 2009 | 144 | 0.080 |
Why?
|
| Enzymes | 1 | 2008 | 25 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2009 | 221 | 0.080 |
Why?
|
| Osteoprotegerin | 1 | 2007 | 11 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.070 |
Why?
|
| Sepharose | 1 | 2007 | 18 | 0.070 |
Why?
|
| Cathepsin K | 1 | 2007 | 16 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2007 | 111 | 0.070 |
Why?
|
| Cell Transplantation | 1 | 2007 | 22 | 0.070 |
Why?
|
| Periodic Acid | 1 | 2006 | 5 | 0.070 |
Why?
|
| Cathepsins | 1 | 2007 | 37 | 0.070 |
Why?
|
| Fibrillar Collagens | 1 | 2007 | 49 | 0.070 |
Why?
|
| Drug Stability | 1 | 2006 | 71 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 24 | 0.070 |
Why?
|
| Osteopontin | 1 | 2006 | 28 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2007 | 206 | 0.070 |
Why?
|
| Middle Aged | 2 | 2014 | 21147 | 0.070 |
Why?
|
| Cholecalciferol | 1 | 2007 | 143 | 0.070 |
Why?
|
| Skin Physiological Phenomena | 1 | 2005 | 13 | 0.070 |
Why?
|
| Porosity | 1 | 2005 | 63 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 155 | 0.060 |
Why?
|
| Cell Polarity | 1 | 2005 | 49 | 0.060 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 45 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2005 | 20 | 0.060 |
Why?
|
| Desmosine | 1 | 2004 | 4 | 0.060 |
Why?
|
| Capillaries | 1 | 2005 | 105 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2004 | 69 | 0.060 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2004 | 24 | 0.060 |
Why?
|
| Astringents | 1 | 2004 | 2 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2005 | 284 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 710 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 770 | 0.060 |
Why?
|
| Biodegradation, Environmental | 1 | 2004 | 92 | 0.060 |
Why?
|
| Models, Biological | 2 | 2005 | 981 | 0.060 |
Why?
|
| Female | 4 | 2014 | 38074 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 201 | 0.060 |
Why?
|
| Thrombosis | 1 | 2005 | 218 | 0.060 |
Why?
|
| Sodium Hydroxide | 1 | 2003 | 5 | 0.060 |
Why?
|
| Transplantation, Heterotopic | 1 | 2003 | 7 | 0.060 |
Why?
|
| Cyanogen Bromide | 1 | 2003 | 14 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 77 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2004 | 223 | 0.060 |
Why?
|
| Biosensing Techniques | 1 | 2004 | 51 | 0.060 |
Why?
|
| Robotics | 1 | 2004 | 56 | 0.060 |
Why?
|
| Biological Assay | 1 | 2004 | 88 | 0.060 |
Why?
|
| Trypsin | 1 | 2003 | 64 | 0.060 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Dermis | 1 | 2003 | 29 | 0.060 |
Why?
|
| Gelatinases | 1 | 2003 | 12 | 0.060 |
Why?
|
| Aluminum | 1 | 2003 | 21 | 0.050 |
Why?
|
| Phospholipids | 1 | 2003 | 108 | 0.050 |
Why?
|
| Phosphorus | 1 | 2003 | 64 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 483 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2003 | 54 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 371 | 0.050 |
Why?
|
| Cell Movement | 1 | 2005 | 630 | 0.050 |
Why?
|
| Solvents | 1 | 2003 | 109 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 179 | 0.050 |
Why?
|
| Cell Death | 1 | 2003 | 329 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 954 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2004 | 368 | 0.050 |
Why?
|
| Protein Conformation | 2 | 2004 | 362 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 101 | 0.050 |
Why?
|
| Heart | 1 | 2006 | 850 | 0.050 |
Why?
|
| Benzyl Compounds | 1 | 2000 | 2 | 0.050 |
Why?
|
| Pentoxifylline | 1 | 2000 | 12 | 0.050 |
Why?
|
| Succinates | 1 | 2000 | 9 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 196 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2000 | 76 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 73 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2000 | 150 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1999 | 25 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 1999 | 53 | 0.040 |
Why?
|
| Circular Dichroism | 1 | 1999 | 99 | 0.040 |
Why?
|
| Lipids | 2 | 1998 | 298 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 659 | 0.040 |
Why?
|
| Software | 1 | 2020 | 418 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1997 | 12 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 134 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 940 | 0.040 |
Why?
|
| Cholesterol | 1 | 1998 | 331 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 1997 | 128 | 0.030 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 20 | 0.030 |
Why?
|
| Microfluidics | 1 | 2015 | 22 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2015 | 59 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 248 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 181 | 0.030 |
Why?
|
| S-Nitrosoglutathione | 1 | 2015 | 87 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2012 | 55 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2015 | 384 | 0.020 |
Why?
|
| Lipid Metabolism | 2 | 2003 | 186 | 0.020 |
Why?
|
| Esters | 1 | 2009 | 22 | 0.020 |
Why?
|
| Capsules | 1 | 2009 | 18 | 0.020 |
Why?
|
| Acrylates | 1 | 2007 | 17 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 481 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 337 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 164 | 0.020 |
Why?
|
| Models, Animal | 1 | 2005 | 252 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 541 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 260 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 500 | 0.010 |
Why?
|
| 2-Propanol | 1 | 2000 | 4 | 0.010 |
Why?
|
| Methanol | 1 | 2000 | 9 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 706 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 490 | 0.010 |
Why?
|